A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Afuresertib (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Proof of concept; Registrational; Therapeutic Use
Sponsors Laekna Therapeutics

13 Jun 2024 Phase has been changed to Phase 3 from 1, this study is now parallel and double-blind, number of treatment arms has been changed to 4 from 2, planned number of patients changed from 20 to 256.
13 Jun 2024 Planned End Date changed from 30 Dec 2024 to 30 Dec 2026.
13 Jun 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Oct 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com